Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherContinuing Education (Invitation Only)

The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis

Giuliano Mariani, Massimo Tonaccehra, Mariano Grosso, Emilio Fiore, Pierpaolo Falcetta, Lucia Montanelli, Brunella Bagattini, Paolo Vitti and Harry William Strauss
Journal of Nuclear Medicine February 2021, jnumed.120.251504; DOI: https://doi.org/10.2967/jnumed.120.251504
Giuliano Mariani
1 Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Tonaccehra
2 Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariano Grosso
3 Regional Center of Nuclear Medicine, University Hospital of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilio Fiore
2 Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierpaolo Falcetta
2 Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Montanelli
2 Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brunella Bagattini
2 Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Vitti
2 Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry William Strauss
4 Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harry William Strauss
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Goiter, an enlargement of the thyroid gland, is a common endocrine abnormality. Constitutional factors, genetic abnormalities, and/or dietary and environmental factors may contribute to the development of nodular goiter. Most patients with non-toxic nodular goiter are asymptomatic or have only mild mechanical symptoms (“globus pharyngis”). Work-up of these patients includes measurement of TSH, fT3, fT4, thyroid auto-antibodies, ultrasound imaging, thyroid scintigraphy, and fine-needle aspiration biopsy of nodules with certain ultrasound and scintigraphic features. Treatment for multinodular goiter includes dietary iodine supplementation, surgery, radioiodine therapy (to decrease thyroid size), and mini-invasive ablation techniques. Hypothyroidism ranges from rare cases of myxedema to more common mild forms (subclinical hypothyroidism). Primary hypothyroidism often has an autoimmune etiology. Clinical presentations differ in the neonate, children, adults and elderly patients. Work-up includes thyroid function tests and ultrasound imaging. Nuclear medicine is primarily used to locate ectopic thyroid tissue in congenital hypothyroidism, or to detect defects in iodine organification with the perchlorate discharge test. Treatment consists of thyroid replacement therapy with L-Thyroxine, adjusting the daily dose to the individual patient’s metabolic and hormonal requirements. Subacute thyroiditis is a self-limited inflammatory disorder of the thyroid gland, often associated with painless or painful swelling of the gland and somatic signs/symptoms. Inflammation disrupts thyroid follicles resulting in a rapid release of stored T4 and T3 causing an initial thyrotoxic phase – often followed by transient or permanent hypothyroidism. Although subacute thyroiditis is often related to a viral infection, no infective agent has been identified. Subacute thyroiditis may be caused by a viral infection in genetically predisposed individuals. Work-up includes lab tests, ultrasound imaging, and radionuclide imaging. Thyroid scintigraphy demonstrates different findings depending on the phase of the illness, ranging from very low-to-absent tracer uptake in the thyroid gland in the hyperthyroid phase, to normal appearance in the late recovery phase. Since subacute thyroiditis is self-limited, treatment is directed toward relief of pain. High-dose nonsteroidal anti-inflammatory drugs are usually the first-line treatment. If severe pain persists, a course of corticosteroids may be necessary. Permanent hypothyroidism develops in up to 15% of patients with subacute thyroiditis, even more than 1 year following presentation.

  • Endocrine
  • Molecular Imaging
  • Radionuclide Therapy
  • diffuse and nodular goiter
  • primary autoimmune hypothyroidism
  • subacute, destructive thyroiditis
  • therapy of benign thyroid disease
  • ultrasound and radionuclide imaging
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis
Giuliano Mariani, Massimo Tonaccehra, Mariano Grosso, Emilio Fiore, Pierpaolo Falcetta, Lucia Montanelli, Brunella Bagattini, Paolo Vitti, Harry William Strauss
Journal of Nuclear Medicine Feb 2021, jnumed.120.251504; DOI: 10.2967/jnumed.120.251504

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis
Giuliano Mariani, Massimo Tonaccehra, Mariano Grosso, Emilio Fiore, Pierpaolo Falcetta, Lucia Montanelli, Brunella Bagattini, Paolo Vitti, Harry William Strauss
Journal of Nuclear Medicine Feb 2021, jnumed.120.251504; DOI: 10.2967/jnumed.120.251504
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Continuing Education (Invitation Only)

  • Fundamental Statistical Concepts in Clinical Trials and Diagnostic Testing
  • Statistical Considerations in the Evaluation of Continuous Biomarkers
Show more Continuing Education (Invitation Only)

Clinical (Oncology: Endocrine/Neuroendocrine)

  • A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
  • Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE
Show more Clinical (Oncology: Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Endocrine
  • molecular imaging
  • Radionuclide Therapy
  • diffuse and nodular goiter
  • primary autoimmune hypothyroidism
  • subacute, destructive thyroiditis
  • therapy of benign thyroid disease
  • ultrasound and radionuclide imaging
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire